

Grace Hwei Ching Tan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2716953/publications.pdf>

Version: 2024-02-01

63
papers

550
citations

687363

13
h-index

752698

20
g-index

63
all docs

63
docs citations

63
times ranked

783
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. <i>International Journal of Hyperthermia</i> , 2017, 33, 690-695.	2.5	39
2	Prospective Quality of Life Study for Colorectal Cancer Patients with Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 2905-2913.	1.5	36
3	Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?. <i>International Journal of Hyperthermia</i> , 2016, 32, 281-288.	2.5	31
4	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Asian Patients: 100 Consecutive Patients in a Single Institution. <i>Annals of Surgical Oncology</i> , 2013, 20, 2968-2974.	1.5	28
5	Gastric peritoneal carcinomatosis - a retrospective review. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 121.	2.0	27
6	Prognostic Relevance of the Peritoneal Surface Disease Severity Score Compared to the Peritoneal Cancer Index for Colorectal Peritoneal Carcinomatosis. <i>International Journal of Surgical Oncology</i> , 2016, 2016, 1-7.	0.6	22
7	Platinum agents and mitomycin C-specific complications in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>International Journal of Hyperthermia</i> , 2018, 34, 595-600.	2.5	22
8	Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: The experience of a tertiary Asian center. <i>Asian Journal of Surgery</i> , 2015, 38, 65-73.	0.4	20
9	A review of 111 anaesthetic patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Singapore Medical Journal</i> , 2017, 58, 488-496.	0.6	20
10	Preoperative platelet-lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>International Journal of Clinical Oncology</i> , 2017, 22, 511-518.	2.2	19
11	201 consecutive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in a single Asian tertiary centre. <i>International Journal of Hyperthermia</i> , 2017, 33, 288-294.	2.5	19
12	The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>World Journal of Surgical Oncology</i> , 2020, 18, 10.	1.9	17
13	Palliative surgery for Krukenberg tumors â€“ 12-year experience and review of the literature. <i>World Journal of Clinical Oncology</i> , 2018, 9, 13-19.	2.3	14
14	Metastatic gastric cancer: Does the site of metastasis make a difference?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 10-17.	1.1	14
15	A machine learning approach to identify predictive molecular markers for cisplatin chemosensitivity following surgical resection in ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 16829.	3.3	12
16	Two rare cases of appendiceal collision tumours involving an appendiceal mucinous neoplasm and carcinoid. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015213938.	0.5	11
17	Exploring the trend in referrals for consideration of CRS and HIPEC to understand the attitudes of clinicians in the development of a national cancer centre programme in peritoneal disease. <i>International Journal of Hyperthermia</i> , 2018, 34, 551-558.	2.5	10
18	A set of molecular markers predicts chemosensitivity to Mitomycin-C following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis. <i>Scientific Reports</i> , 2019, 9, 10572.	3.3	10

#	ARTICLE	IF	CITATIONS
19	Novel management of a giant cervical myoma in a premenopausal patient. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-221408.	0.5	10
20	Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>International Journal of Clinical Oncology</i> , 2018, 23, 989-998.	2.2	9
21	Postoperative Inflammatory Marker Surveillance in Colorectal Peritoneal Carcinomatosis. <i>Annals of Surgical Oncology</i> , 2021, 28, 6625-6635.	1.5	9
22	Surgical Management of Colorectal Peritoneal Metastases: Treatment and Outcomes Compared with Hepatic Metastases. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 170-176.	1.3	8
23	Malignancy arising in a 41-year-old colonic interposition graft. <i>Asian Journal of Surgery</i> , 2016, 39, 45-47.	0.4	8
24	Proposed radiological criteria for preoperative determination of resectability in peritoneal-based malignancies. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 337-343.	1.8	8
25	Uncommon indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Pleura and Peritoneum</i> , 2017, 2, 129-136.	1.2	8
26	High-grade complication is associated with poor overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 984-994.	2.2	7
27	Axillary Lymph Node Dissection in Angiosarcomas of the Breast: An Asian Institutional Perspective. <i>Sarcoma</i> , 2020, 2020, 1-5.	1.3	7
28	Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis. <i>Cell Reports Medicine</i> , 2022, 3, 100526.	6.5	7
29	Unresectability during open surgical exploration in planned cytoreductive surgery and hyperthermic intraperitoneal chemotherapy*. <i>International Journal of Hyperthermia</i> , 2016, 32, 889-894.	2.5	5
30	Urological reconstruction after pelvic oncological surgery: A single institution experience. <i>Asian Journal of Surgery</i> , 2017, 40, 389-395.	0.4	5
31	A solitary fibrous tumour mimicking an aggressive angiomyxoma/liposarcoma. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2016-218202.	0.5	5
32	Retrospective quality of life study in patients with retroperitoneal sarcoma in an Asian population. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 270.	2.4	5
33	Effect of the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on the treatment of colorectal peritoneal metastasis. <i>Asian Journal of Surgery</i> , 2022, 45, 339-345.	0.4	5
34	Hypoglycaemia in a 63-Year-Old Female with a Large, Recurrent, Metastatic Gastrointestinal Stromal Tumour (GIST). <i>Journal of Gastrointestinal Cancer</i> , 2011, 42, 263-265.	1.3	4
35	Is multivisceral resection in locally advanced gastrointestinal stromal tumours an acceptable strategy?. <i>ANZ Journal of Surgery</i> , 2017, 87, 477-482.	0.7	4
36	Is the Memorial Sloan Kettering Cancer Centre (MSKCC) sarcoma nomogram useful in an Asian population?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e466-e472.	1.1	4

#	ARTICLE	IF	CITATIONS
37	Does having a gastrectomy delay time to feeding and prolong hospital stay in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?. <i>International Journal of Hyperthermia</i> , 2018, 34, 518-523.	2.5	4
38	The impact of urological resection and reconstruction on patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>Asian Journal of Urology</i> , 2018, 5, 194-198.	1.2	4
39	Treatment of gastrointestinal tumor (GIST) of the rectum requiring abdominoperineal resection following neoadjuvant imatinib: a cost-effectiveness analysis. <i>Clinical Sarcoma Research</i> , 2020, 10, 13.	2.3	4
40	Neoadjuvant tyrosine kinase inhibitors in rectal gastrointestinal stromal tumours: a provision for enhanced oncological and functional outcomes. <i>International Journal of Clinical Oncology</i> , 2021, 26, 913-921.	2.2	4
41	Management of synchronous lateral pelvic nodal metastasis in rectal cancer in the era of neoadjuvant chemoradiation: A systemic review. <i>World Journal of Gastrointestinal Surgery</i> , 2020, 12, 247-258.	1.5	4
42	Role of upfront surgery for recurrent gastrointestinal stromal tumours. <i>ANZ Journal of Surgery</i> , 2016, 86, 910-915.	0.7	3
43	Tumor biology remains the main determinant of prognosis in retroperitoneal sarcomas: a 14-year single-center experience. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e458-e465.	1.1	3
44	Biphasic learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: technical competence and refinement of patient selection. <i>Pleura and Peritoneum</i> , 2018, 3, 20180122.	1.2	3
45	Surgical management and hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 508-512.	1.4	3
46	ASO Author Reflections: Postoperative Inflammatory Markers as a Surveillance Tool in Colorectal Peritoneal Carcinomatosis. <i>Annals of Surgical Oncology</i> , 2021, 28, 6636-6637.	1.5	3
47	Radiation-associated peritoneal angiosarcoma. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2016-217887.	0.5	3
48	Relevance of enlarged cardiophrenic lymph nodes in determining prognosis of patients with advanced ovarian cancer. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-221450.	0.5	3
49	Implications of peritoneal cancer index distribution on patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Pleura and Peritoneum</i> , 2022, 7, 95-102.	1.2	3
50	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer with peritoneal metastasis: a prospective registry study on 41 patients. <i>Pleura and Peritoneum</i> , 2017, 2, 171-179.	1.2	2
51	CA-125: an inaccurate surveillance tool immediately after cytoreductive surgery and hyperthermic intraoperative chemotherapy (CRS-HIPEC)?. <i>International Journal of Hyperthermia</i> , 2018, 34, 585-588.	2.5	2
52	P.R.O.P.S. – A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>World Journal of Surgical Oncology</i> , 2019, 17, 138.	1.9	2
53	Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis. <i>ANZ Journal of Surgery</i> , 2020, 90, 1958-1964.	0.7	2
54	Predicting Early and Late Readmissions Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 6613-6624.	1.5	2

#	ARTICLE	IF	CITATIONS
55	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastrointestinal cancers: fad or standard of care?. Singapore Medical Journal, 2018, 59, 116-120.	0.6	2
56	Pathological Outcome in Men with Prostate Cancer Suitable for Active Surveillance after Radical Prostatectomy. Proceedings of Singapore Healthcare, 2012, 21, 102-108.	0.6	1
57	Surgical Management of Metastatic Colorectal Cancer: A Single-Centre Experience on Oncological Outcomes of Pulmonary Resection vs Cytoreductive Surgery and HIPEC. Journal of Gastrointestinal Cancer, 2017, 48, 353-360.	1.3	1
58	Dedifferentiated liposarcoma with a rare presentation of disseminated intraperitoneal sarcomatosis: A case report. International Journal of Surgery Case Reports, 2019, 60, 331-335.	0.6	1
59	Gene Expression Changes Associated with Dedifferentiation in Liposarcoma Predict Overall Survival. Cancers, 2021, 13, 3049.	3.7	1
60	Palliative Gastrointestinal Surgery in Patients With Advanced Peritoneal Carcinomatosis: Clinical Experience and Development of a Predictive Model for Surgical Outcomes. Frontiers in Oncology, 2021, 11, 811743.	2.8	1
61	Reply to letter: Nephrotoxic synergism of cisplatin and mitomycin-C for hyperthermic intraperitoneal chemotherapy and cytoreductive surgery by Kapoor R, Robinson K and Badgwell B. International Journal of Hyperthermia, 2018, 34, 602-602.	2.5	0
62	ASO Visual Abstract: Predicting Early and Late Readmissions after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2021, 28, 604-605.	1.5	0
63	Can baseline quality of life scores predict for morbidity and survival after CRS and HIPEC: a prospective study of 151 patients. Pleura and Peritoneum, 2022, 7, 63-75.	1.2	0